Pioneering Myeloprotective Drugs for Cancer Patients
Zymeron, a preclinical pharmaceutical startup, is dedicated to developing myeloprotective and osteoprotective drugs that preserve the health and function of the osteomyeloid structure, as well as its functional interplay with the circulatory systems, i.e., hematopoietic, cardiovascular and cerebrovascular systems. MyeloShield is transforming the clinical management of myelosuppression and cytopenia from reaction to prevention with the goal to improve the quality of life and medication adherence for chemoradiotherapy patients.
Our Technologies
Our innovators developed drug delivery and formulation technologies to bridge gaps in pharmaceutical sciences that are manifested by multiple unmet clinical needs.
Bone Marrow Drug Delivery Platform – Our proprietary peptide drug conjugate (PDC) demonstrated its advantages and benefits in delivering a cytoprotective molecules to protect hematopoietic stem and progenitor cells from chemotherapy or radiation induced myelotoxicity.
Reformulate Poorly Soluble Drugs to Injectables – Converting insoluble or poorly soluble small molecule drugs to highly soluble non-covalent molecular variants is a requirement to repurpose these oral drugs as emergency medicine and for patients who experience dysphagia.
Our Partners
We have an extended list of partners in academia, industry, government, and non-profit organizations. We work closely with numerous government agencies including the Department of Defense and the Department of Health and Human Services to develop innovative products to meet the nation’s health and defense needs. We commercialize advanced materials and health-related technologies and bring them to market in partnership with commercial entities.